Michel Warny

Summary

Affiliation: Acambis Inc
Country: USA

Publications

  1. ncbi Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe
    Michel Warny
    Acambis Inc, Cambridge, MA, USA
    Lancet 366:1079-84. 2005
  2. ncbi Active and passive immunization against Clostridium difficile diarrhea and colitis
    Paul J Giannasca
    Acambis Inc, 38 Sidney Street, Cambridge, MA 02139, USA
    Vaccine 22:848-56. 2004
  3. ncbi Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A
    Samer Aboudola
    Gastroenterology Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    Infect Immun 71:1608-10. 2003
  4. ncbi Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea
    Stavros Sougioultzis
    Gastroenterology Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, 02215, USA
    Gastroenterology 128:764-70. 2005

Collaborators

Detail Information

Publications4

  1. ncbi Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe
    Michel Warny
    Acambis Inc, Cambridge, MA, USA
    Lancet 366:1079-84. 2005
    ..We characterised the dominant strain of this epidemic to determine whether it produces higher amounts of toxins A and B than those produced by non-epidemic strains...
  2. ncbi Active and passive immunization against Clostridium difficile diarrhea and colitis
    Paul J Giannasca
    Acambis Inc, 38 Sidney Street, Cambridge, MA 02139, USA
    Vaccine 22:848-56. 2004
    ..An active vaccine and various immunotherapeutic strategies under evaluation may prove to be effective against severe or relapsing C. difficile infection...
  3. ncbi Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A
    Samer Aboudola
    Gastroenterology Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    Infect Immun 71:1608-10. 2003
    ..These findings support the feasibility of using a vaccine to protect high-risk individuals against C. difficile-associated diarrhea and colitis...
  4. ncbi Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea
    Stavros Sougioultzis
    Gastroenterology Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, 02215, USA
    Gastroenterology 128:764-70. 2005
    ..The results of this study support the feasibility of active vaccination against C difficile and its toxins in high-risk individuals but must be validated in larger, randomized, controlled trials...